Congress recently made a number of changes to Medicare's "Part D" prescription drug benefit. The changes were part of President Joe Biden's signature legislation, the Inflation Reduction Act. The legi ...
While recent advances in medicine have created prescription anti-obesity GLP-1 medications — like Ozempic, Wegovy, and ...
The U.S. fiscal outlook has dramatically deteriorated since the last time we ran a surplus in 2001, and President Joe Biden — like Democratic and Republican presidents before him — ...
The Medicare Annual Election Period (AEP) is a critical time for beneficiaries to review and update their coverage. In a ...
President-elect Donald Trump has nominated Dr. Mehmet Oz to lead the Centers for Medicare and Medicaid Services (CMS), ...
With fewer Part D plans and a $2,000 out-of-pocket cap, beneficiaries must rethink their Medicare drug coverage for 2025.
The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate prices for its costliest ...
Millions of Americans would be eligible to have popular drugs used for weight loss like Wegovy or Ozempic covered by Medicare ...
The U.S. pharmaceutical industry is attempting to delay the timeline for Medicare's drug price negotiations following the ...
A record-low number of Medicare Part D plans could cause greater Medicare Advantage enrollment, which may not be a good thing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback